Alzheimer's Disease (AD)

Alzheimer's Disease (AD) is the indication for 17 drugs in DrugBank. It is covered by 22 curated, structured indications.

Also known as: Alzheimer Disease · Alzheimer's Disease · Alzheimer’s · Alzheimers Disease · Alzheimers' Disease
Classified under: Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Mental Disorders
Nervous System Diseases
Indicated drugs: Aducanumab
Cerebrolysin
Donanemab
Donepezil
Florbetaben F-18
Florbetapir F-18
Florquinitau (18F)
Flortaucipir F-18
Flutemetamol (18F)
Galantamine
Idebenone
Lecanemab
Memantine
Olanzapine
Prazosin
Thioridazine
Trazodone

Resolves to

Vocabularies

MeSHM0000842ICD-10G30SNOMED CT154994001MedDRA10001896UMLSC0002395

What you can answer from here — as of October 25, 2026

17Indicated drugsWith each drug's targets and mechanism

Listed above

22Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

1,820Clinical trialsPhase, status and sponsor resolved per trial

5Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Alzheimer's Disease (AD) share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.